Analysis of long-term cost-utility comparing a once-weekly GLP-1 receptor agonist versus a DPP-4 inhibitor for high cardiovascular risk type 2 diabetes in China.
Key Takeaways
- Multicenter real-world study found loxenatide reduced 3P-MACE versus DPP-4 inhibitors with HR 0.58
- Loxenatide lowered non-fatal stroke by 48% and heart failure hospitalization by 68% versus sitagliptin
- Five-state Markov model over 40 years assessed incremental cost-effectiveness using Chinese cost and utility inputs